Carcinogenesis is characterized by an abnormal regulation of the cell cycle. Regulators of the cell cycle such as
cyclin E play an important role in
neoplasia and may be correlated with prognosis. The clinical significance of the expression of
cyclin E in stage III
colorectal carcinoma has not yet been investigated. The expression of
cyclin E was evaluated in 49 patients. Using a multivariate analysis, the expression of
cyclin E in the
tumor at diagnosis was compared with various clinicopathological variables, including age, gender,
tumor site,
tumor size,
tumor differentiation and lymph node involvement. There were more node-positive cases in the
cyclin E-negative group than in the
cyclin E-positive group (P=0.003). However, there was no correlation between the degree of
cyclin E expression and the clinical data. In conclusion, our data suggest that overexpression of
cyclin E does not predict the clinical outcome in
colorectal cancer stage III. Negative
cyclin E staining may be associated with lymph node involvement.